Press Releases

Date Title and Summary Additional Formats
Toggle Summary CHF Solutions Webinar Highlighted Importance of Fluid Management in Patients Treated for COVID-19
Proper Control of Fluids Routinely Administered to Patients with Acute Respiratory Infections Play Important Role in Successful Outcomes EDEN PRAIRIE, Minn. , March 18, 2020 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to improving the lives of patients
View HTML
Toggle Summary CHF Solutions to Host Clinician Webinar on Use of Ultrafiltration for Volume Management in Patients Treated for COVID-19
EDEN PRAIRIE, Minn. , March 13, 2020 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS) today announced the company will host an interactive, physician-led webinar to discuss the importance of volume management in the treatment of patients with COVID-19.  Dr.
View HTML
Toggle Summary CHF Solutions, Inc. Announces Fourth Quarter Financial Results and Provides Company Update
EDEN PRAIRIE, Minn. , March 03, 2020 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (Nasdaq: CHFS) announced today its results for the fourth quarter and year ended December 31, 2019 , which included the following highlights: Received 510(k) clearance in the U.S.
View HTML
Toggle Summary CHF Solutions receives 510(k) clearance for Aquadex SmartFlow™ system in Pediatric Patients Weighing 20kg or More
EDEN PRAIRIE, Minn. , Feb. 26, 2020 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS) today announced FDA 510(k) clearance in the U.S. of its next generation Aquadex SmartFlow console for use in adult and pediatric patients who weigh 20kg or more. The console is a simple, gentle, and smart solution
View HTML
Toggle Summary CHF Solutions, Inc. To Announce Fourth Quarter and Year-End 2019 Financial Results on March 3, 2020
EDEN PRAIRIE, Minn. , Feb. 25, 2020 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (NASDAQ: CHFS) announces today that its fourth quarter and year-end 2019 financial results will be released on Tuesday, March 3, 2020 . The company will host a conference call and webcast at 9:00 AM ET that morning, during
View HTML
Toggle Summary CHF Solutions Expands Commercial Presence in Europe with Distribution Arrangement for Germany, Austria and Switzerland
EDEN PRAIRIE, Minn. , Feb. 12, 2020 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS) today announced the initiation of distribution agreements covering Germany , Austria and Switzerland with Neucomed Group and its affiliates, further expanding its commercial presence in the European Union .
View HTML
Toggle Summary CHF Solutions, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
EDEN PRAIRIE, Minn. , Feb. 11, 2020 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (NASDAQ: CHFS), today announced that, on February 5, 2020 , the independent directors approved five equity awards under CHF Solution’s New-Hire Equity Incentive Plan, as material inducements to five individuals entering
View HTML
Toggle Summary CHF Solutions Receives CE Mark for its New Aquadex SmartFlow™ Console
EDEN PRAIRIE, Minn. , Feb. 05, 2020 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS) today announced the receipt of a CE Mark for its Aquadex SmartFlow console, its next generation ultrafiltration system. The console is a simple, flexible and smart solution for treatment of patients suffering from
View HTML
Toggle Summary CHF Solutions Expands its Patent Portfolio with Four Applications for Innovations for Aquapheresis Therapy
EDEN PRAIRIE, Minn. , Jan. 30, 2020 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS) today announced the filing of four patent applications with the United States Patent and Trademark Office (USPTO) to protect new innovations for use in aquapheresis therapy and further strengthen the company’s
View HTML
Toggle Summary CHF Solutions, Inc. Announces Closing of $9.66 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option
EDEN PRAIRIE, Minn. , Jan. 28, 2020 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (NASDAQ:CHFS) today announced the closing of an underwritten public offering of units for gross proceeds of approximately $9.66 million , which includes the full exercise of the underwriter's over-allotment option to
View HTML